Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Opemalirsen · 1 trial · 1 indication
Area under the concentration-time curve from zero to infinity
Area under the concentration-time curve from zero to the last measurable concentration
Maximum observed plasma concentration
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Healthy participants will receive a single subcutaneous injection of AZD2373. |
| Group 2 | EXPERIMENTAL | Severe renal impairment participants will receive a single subcutaneous injection of AZD2373. |
| Group 3 | EXPERIMENTAL | Moderate renal impairment participants will receive a single subcutaneous injection of AZD2373 |
| Group 4 | EXPERIMENTAL | Mild renal impairment participants will receive a single subcutaneous injection of AZD2373 |
| Name | Type | Description |
|---|---|---|
| Opemalirsen (AZD2373) | DRUG | Single, subcutaneous injection of AZD2373 |
Inclusion Criteria: * Participants are eligible to be included in the study only if all of the following criteria apply: Age 1. Participant must be 18 to 80 years of age, inclusive, at the time of signing the informed consent. Type of Participant and Disease Characteristics For all participants, ...
Opemalirsen is an investigational small molecule being studied for use in renal impairment. It is being evaluated for its effects on the pharmacokinetics, safety, and tolerability in patients with renal impairment. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Opemalirsen is being developed by AstraZeneca PLC, a multinational pharmaceutical company. AstraZeneca is listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in patients with renal impairment.
Opemalirsen is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for its safety, tolerability, and pharmacokinetics in patients with renal impairment.
Opemalirsen has one completed clinical trial registered under NCT07154901. This Phase 1 study investigated the effects of renal impairment on the pharmacokinetics, safety, and tolerability of Opemalirsen (AZD2373). The trial enrolled 35 participants in the United States and included healthy volunteers.
Yes, Opemalirsen is also known as AZD2373. The clinical trial NCT07154901 refers to the drug as Opemalirsen (AZD2373), confirming that these names refer to the same investigational compound being developed by AstraZeneca.